To better understand the healthcare resource utilization of patients with differing manifestations of HPP, we reviewed 3 representative cases within the UK National Health Service network, including 1 patient with perinatal HPP who received treatment with asfotase alfa, a human recombinant TNSALP enzyme replacement therapy (Strensiq®; Alexion Pharmaceuticals, Inc., New Haven, CT) that is approved for the treatment of HPP in several countries [35–39]. The gene discussed is ALPL; the disease is hypophosphatasia.